COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come ...

The data showed a surprisingly compelling overall survival (OS) benefit. TheBraftovi combination regimen received Food and ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...

Around 20% of these centres have expanded their footprint across three or more cities, signalling a trend towards multi-city ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

Pfizer has shared positive survival results from a late-stage study of its Braftovi (encorafenib) regimen in patients with ...